10x Genomics $TXG Shares Sold by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management S.A. decreased its stake in 10x Genomics by 1.3%, owning approximately 1.39% of the company, valued at $19.8 million after selling 23,073 shares.
• Insider transactions showed CEO Serge Saxonov and another insider sold shares on August 22, resulting in a combined total of 39,149 shares sold in the last ninety days, valued at over $539,000.
• 10x Genomics reported quarterly earnings of $0.28 per share, surpassing analyst expectations, and generated revenue of $172.91 million, up 12.9% year-over-year.

Assenagon Asset Management S.A. cut its stake in shares of 10x Genomics (NASDAQ:TXG - Free Report) by 1.3% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 1,711,561 shares of the company's stock after selling 23,073 shares during the quarter. Assenagon Asset Management S.A. owned about 1.39% of 10x Genomics worth $19,820,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in TXG. GAMMA Investing LLC boosted its position in shares of 10x Genomics by 81.8% in the 1st quarter. GAMMA Investing LLC now owns 3,586 shares of the company's stock worth $31,000 after buying an additional 1,614 shares in the last quarter. GF Fund Management CO. LTD. purchased a new stake in shares of 10x Genomics in the 4th quarter worth about $32,000. Signaturefd LLC boosted its position in shares of 10x Genomics by 134.3% in the 1st quarter. Signaturefd LLC now owns 4,203 shares of the company's stock worth $37,000 after buying an additional 2,409 shares in the last quarter. Whittier Trust Co. purchased a new stake in shares of 10x Genomics in the 1st quarter worth about $41,000. Finally, PNC Financial Services Group Inc. boosted its position in shares of 10x Genomics by 153.6% in the 1st quarter. PNC Financial Services Group Inc. now owns 5,150 shares of the company's stock worth $45,000 after buying an additional 3,119 shares in the last quarter. 84.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, CEO Serge Saxonov sold 9,348 shares of the company's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $128,908.92. Following the completion of the transaction, the chief executive officer directly owned 945,892 shares of the company's stock, valued at $13,043,850.68. This represents a 0.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Benjamin J. Hindson sold 7,486 shares of the company's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $13.79, for a total transaction of $103,231.94. Following the completion of the transaction, the insider directly owned 440,888 shares of the company's stock, valued at approximately $6,079,845.52. The trade was a 1.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 39,149 shares of company stock valued at $539,865 in the last ninety days. Insiders own 10.03% of the company's stock.

10x Genomics Price Performance

TXG opened at $13.04 on Tuesday. The firm has a market capitalization of $1.62 billion, a P/E ratio of -18.63 and a beta of 2.00. The firm's 50 day moving average is $13.30 and its 200-day moving average is $10.90. 10x Genomics has a 52-week low of $6.78 and a 52-week high of $23.16.

10x Genomics (NASDAQ:TXG - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.35) by $0.63. The company had revenue of $172.91 million for the quarter, compared to analyst estimates of $139.36 million. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The business's quarterly revenue was up 12.9% on a year-over-year basis. During the same quarter last year, the firm posted ($0.32) earnings per share. 10x Genomics has set its Q3 2025 guidance at EPS. Equities analysts expect that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the stock. Canaccord Genuity Group set a $16.00 price objective on shares of 10x Genomics in a research report on Monday, August 11th. UBS Group upped their target price on shares of 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a report on Friday, August 8th. Bank of America upped their target price on shares of 10x Genomics from $12.00 to $13.00 and gave the company a "neutral" rating in a report on Thursday, June 26th. Zacks Research lowered shares of 10x Genomics from a "strong-buy" rating to a "hold" rating in a report on Friday, September 5th. Finally, Wall Street Zen lowered shares of 10x Genomics from a "buy" rating to a "hold" rating in a report on Saturday, September 13th. Six investment analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, 10x Genomics has a consensus rating of "Hold" and an average price target of $13.65.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.

Want to see what other hedge funds are holding TXG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for 10x Genomics (NASDAQ:TXG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.